Steelhead Partners »

Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Steelhead Partners

Quarter-by-quarter ownership of Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Steelhead Partners from 13F filings

Historical chart of Steelhead Partners investment in Alnylam Pharmaceuticals Inc Note 1.000 9/1

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals Inc Note 1.000 9/1 held by Steelhead Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals Inc Note 1.000 9/1 by Steelhead Partners

Quarter filed Position value Share count Share price at filing
2024-03-31 $33B 35M 939.01
2023-12-31 $55B 55M 991.18
2023-09-30 $51B 55M 929.45

More positions owned by Steelhead Partners

Sealtd 0 1/4 09/15/26 Note 0.250% 9/1 (Principal)
Spot 0 03/15/26 Note 3/1 (Principal)
Net 0 08/15/26 Note 8/1 (Principal)
DXCM 0 1/4 11/15/25 Note 0.250%11/1 (Principal)
Sedg 0 09/15/25 Note 9/1 (Principal)
Idcc 2 06/01/24 Note 2.000% 6/0 (Principal)
Trip 0 1/4 04/01/26 Note 0.250% 4/0 (Principal)
Ions 0 04/01/26 Note 4/0 (Principal)
FVRR 0 11/01/25 Note 11/0 (Principal)
Box 0 01/15/26 Note 1/1 (Principal)
CFLT 0 01/15/27 Note 1/1 (Principal)
Alrm 0 01/15/26 Note 1/1 (Principal)
Etsy 0 1/4 06/15/28 Note 0.250% 6/1 (Principal)
Uber 0 12/15/25 Note 12/1 (Principal)
SQ 0 05/01/26 Note 5/0 (Principal)

View all positions for Steelhead Partners

Top funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1

Ubs Global Asset Management Americas
Calamos Advisors
Opti Capital Management
Steelhead Partners
Aequim Alternative Investments
Citadel Advisors
Davidson Kempner Capital Management
Lazard Asset Management
Readystate Asset Management
D. E. Shaw & Co
Zazove Associates
Shenkman Capital Management
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Capstone Investment Advisors
MacKay Shields

View all funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1